© 2 0 1 8 I n d I a n J o u r n a l o f P a t h o l o g y a n d M I c r o b I o l o g y | P u b l I s h e d b y W o l t e r s K l u W e r -M e d K n o W ABSTRACT Background: It is still a matter of debate regarding the association of JAK2V617F mutation with thrombosis in BCR-ABL negative CMPN patients. The role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs is yet unequivocal. Aims: To clarify the contribution of JAK2V617F mutation in thrombosis in CMPN patients. Settings and Design: This retrospective study was done to evaluate role of JAK2V617F mutation in thrombosis in CMPNs. Materials and Methods: 65 CMPN patients (PV, ET and PMF) were analyzed for JAK2V617F mutation using ARMS-PCR and detailed history of thrombosis was recorded in these patients. Statistical Analysis: P values were 2 tailed, and statistical significance was set at P < 0.05. Results: 46/65 were males and 19/65 were females [M: F: 2.4:1] with median age 46 years [range, 14-80 years]. Patients had median Hb 15.6 g/dl [range, 5.1-20.3], median TLC 10.7 × 10 9 /l [range 2.4-216] and platelet count 360 × 10 9 /l [range , 20-1859]. 32 were JAK2V617F positive and 33 were negative for this mutation. On comparing the prevalence of thrombosis in JAK2V617F positive patients with JAK2V617F negative patients, we observed that 20/32 (62.5%) JAK2V617F positive patients had thrombosis as compared to 16/33 (48%) in JAK2V617F negative patients (P = 0.04). We observed significant association of JAK2V617F mutation with thrombosis, however no association of this mutation with thrombosis was observed among the JAK2V617F negative patients. Conclusion: Our study suggests that JAK2V617F mutation may increase the risk of thrombosis in CMPNs. This finding could lead to risk stratification, setting up the treatment strategy in CMPNs.
INTRODUCTION
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic myeloproliferative neoplasms (CMPN) characterized by clonal proliferation of abnormal hematopoietic stem cells. The understanding of the CMPN pathogenesis significantly improved after the discovery of JAK2V617F mutation in exon 14, which involves 95% of PV and 50% to 60% of ET and PMF patients, respectively. [1, 2] Clinical manifestations of these CMPNs are characterized by thrombotic and hemorrhagic complications and propensity to transform into acute leukemia. Thrombosis remains the leading cause for morbidity and mortality in myeloproliferative disorder representing the initial presentation for 12%-39% of patients subsequently diagnosed with PV and 11%-25% for those given the diagnosis of ET and PMF. [3] Current management recommendations for these disorders emphasize the importance of prognostic stratification, especially with regard to thrombotic risk, in determining the treatment strategy. Well-described risk factors for thrombosis identified in CMPN patients include increasing age, a prior thrombotic event, raised hematocrit, and in vitro occurrence of spontaneous megakaryocyte colony formation. [4] [5] [6] [7] [8] [9] One of the potential novel risk factors for thrombosis which are currently being explored include JAK2V617F mutation. JAK2V617F mutation has been reported to be associated with This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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leukocytosis and platelet activation which may be a possible explanation underlying the increased risk of thrombosis in CMPN patients. [7, 10, 11] There is still a diagnostic dilemma and mixed opinions regarding the associative role of JAK2V617F mutation in increasing the risk of thrombosis in CMPNs. [6, [10] [11] [12] [13] [14] [15] [16] [17] To the best of our knowledge, there is paucity regarding the role of JAK2V617F mutation in augmenting the risk of thrombosis in CMPN patients in India. In view of this, we conducted this study to access the possible role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs.
MATERIALS AND METHODS
This is a retrospective study conducted at the All India Institute of Medical Sciences, New Delhi, India, during the year 2014-2016. A total of 65 CMPN patients (PV, PMF, and ET) were available for this study and these patients were diagnosed as per the WHO criteria. Chronic myeloid leukemia cases were excluded from the study. Five milliliter peripheral blood sample was collected in 1.6% ethylenediaminetetraacetic acid solution. DNA was extracted from peripheral blood sample using commercially available DNA extraction kit. All the samples were screened for JAK2V617F mutation using amplification refractory mutational system-polymerase chain reaction, and results were analyzed using 3% agarose gel [ Figure 1 ]. Detailed history of thrombosis was recorded in these patients for correlation with JAK2V617F mutation. Ethical approval for the study protocol was obtained and written informed consent was taken from all patients.
Statistical analysis
Statistical analysis was performed using Stata 11. P values were two-tailed, and statistical significance was set at P < 0.05.
Comparison between categorical variables was performed using
Chi-square test except where numbers <5 were encountered in which case Fisher's exact test was used.
RESULTS
Baseline characteristics and hematological parameters of the patients are summarized in Table 1 . Forty-six were male and 19 were female (M: F: 2.4:1) with median age of 46 years (range, 14-80 years). Among hematological parameters, median Hb was 15.6 g/dl (range, 5.1-20.3), median TLC was 10.7 × 10 9 /L (range 2.4-216), and platelet count was 360 × 10 9 /L (range, 20-1859). Out of 65 patients, 32 were JAK2V617F positive and 33 were negative for JAK2V617F mutation. Out of 32 JAK2V617F-positive cases, 20 (62.5%) patients had thrombosis and 12 (37.5%) patients had no history of thrombosis. Out of 33 JAK2V617F negative cases, 16 (48%) patients had thrombosis and 17 (52%) patients had no history of thrombosis. On comparing the prevalence of thrombosis in JAK2V617F-positive patients with JAK2V617F-negative patients, we observed that 20/32 (62%) JAK2V617F-positive patients had thrombosis as compared to 16/33 (48%) in JAK2V617F-negative patients (P = 0.04) [ 
DISCUSSION
PV, ET, and PMF are Philadelphia-negative CMPNs with cardinal features of an increased red cell mass in PV, raised platelet count in ET, and bone marrow fibrosis in PMF with thrombosis, hemorrhage, and acute leukemic transformation as major complications. [18, 19] JAK2V617F point mutation is usually identified in most patients with PV (95%) and in significant proportion of patients with ET (50%-60%) and PMF (50%-60%). [20] In the era of a better molecular understanding of CMPNs, much attention has been focused on whether the presence of JAK2V617F has any bearing on thrombotic risk. Several hypothetical mechanisms exist, i.e., JAK2 mutation augments thrombotic risk by increasing Hb and TLC, platelet activation and hyperresponsiveness through impairment of cMPL signal transduction, and elevated platelet-WBC aggregates through increased P-selectin expression. [21] [22] [23] [24] There are mixed views regarding the association of JAK2V617F mutation with thrombosis in CMPNs. Some studies have depicted the possible role of this mutation in thrombosis while others have contrary opinion [ Table 3 ]. [6, [12] [13] [14] [15] [16] [17] Table 3 ]. [6, [12] [13] [14] [15] [16] [17] 
CONCLUSION
Our study suggests that JAK2V617F mutation may increase the thrombotic risk in CMPN patients. This finding could further lead to risk stratification, setting up the treatment strategy in these patients. However, more randomized studies in larger subset of patients are required to confirm our findings. India Yes 62.5 versus 48 CMPN: Chronic myeloproliferative neoplasms
